NVCR News and Press, NovoCure Limited From 10/25/18

NovoCure ( NVCR ) Q3 results: Revenues: $64.8M (+29.3%); Net Loss: ($11.7M) (+1.7%); Loss Per Share: ($0.13) (unch). More news on: NovoCure, Healthcare stocks news, Earnings news and commentary, Read more ...

NovoCure (NASDAQ: NVCR ): Q3 GAAP EPS of -$0.13 beats by $0.02 . More news on: NovoCure, Earnings news and commentary, Healthcare stocks news, Read more ...

Quarterly net revenues of $64.8 million, representing 29 percent growth versus the third quarter 2017 and 5 percent growth versus the second quarter 2018 Humanitarian device exemption (HDE) application submitted to FDA for approval in malignant pleural mesothelioma Novocure (NASD...

Shares of NovoCure ( NVCR ) were trading at $18/share when I introduced them as "revolutionizing cancer treatment" and at $21/share when I called them a "high conviction" pick. Just a few months later, shares in NovoCure trade comfortably over $45/share and for good reason. NovoCure is see...

Novocure (NASDAQ: NVCR ) and Zai Lab (NASDAQ: ZLAB )  signs an exclusive license agreement for Tumor Treating Fields, including the brand name Optune, in Greater China and a global strategic development collaboration. More news on: NovoCure, Zai Lab Ltd., Healthcare stocks news, ...

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday , September 11. Cramer started the show by remembering the tragic events of Sept. 11, 2001 and the collapse of Lehman Brothers. Despite that, he repeated his mantra, "There is always a bull market ...

Zai Lab granted license to commercialize oncology platform technology Tumor Treating Fields, including the brand name Optune®, in China, Hong Kong, Macau and Taiwan Zai Lab will support enrollment of Chinese patients to certain clinical trials investigating Tumor Treating Fields, ...